NuBiyota focuses on developing innovative microbiome-based therapies aimed at addressing various health conditions. The company leverages advanced technologies to harness the power of the human microbiome, which plays a crucial role in maintaining health and preventing disease. Their approach includes the use of live biotherapeutic products (LBPs) that are designed to restore or modify the microbiome to achieve therapeutic benefits. This technology is particularly relevant in treating gastrointestinal disorders and other conditions influenced by microbial imbalances.

In addition to LBPs, NuBiyota employs cutting-edge research methodologies to identify and characterize beneficial microorganisms. Their scientific framework integrates genomics, metabolomics, and bioinformatics to understand the interactions between the microbiome and host health. By utilizing these technologies, NuBiyota aims to develop targeted therapies that can effectively modulate the microbiome, ultimately leading to improved patient outcomes and a deeper understanding of microbiome-related diseases.

United States

NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is associated with infections, chronic disease and even neurological dysfunction.

NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications

NuBiyota

Company Details